RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1160/TH08-11-0761
Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease
Financial support: This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (nos. 18209023, 18018021, and 19659149 to Y.Y.).
Publikationsverlauf
Received:
24. November 2008
Accepted after major revision:
30. Januar 2009
Publikationsdatum:
24. November 2017 (online)
Summary
Chronic kidney disease (CKD) is a serious clinical condition that is associated with a high incidence of cardiovascular disease and end-stage renal disease. Although CKD has been recognised as a risk factor for myocardial infarction (MI), genetic factors for predisposition to MI in individuals with CKD have remained largely unknown. The purpose of the present study was to identify genetic variants that confer susceptibility to MI in Japanese individuals with CKD. The study subjects comprised 1,339 Japanese individuals with CKD, including 496 subjects with MI and 843 controls. The genotypes for 248 polymorphisms of 181 candidate genes were determined by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. An initial screen of allele frequencies by the chi-square test revealed that the 11496G→A (Arg353Gln) polymorphism of F7 (rs6046) was significantly (false discovery rate <0.05) associated with the prevalence of MI in individuals with CKD. Subsequent multivariable logistic regression analysis with adjustment for covariates and a stepwise forward selection procedure also revealed that this polymorphism was significantly (p <0.005) associated with MI, with the variant A (Gln) allele protecting against this condition. Determination of genotype for the 11496G→A (Arg353Gln) polymorphism of F7 may prove informative for assessment of the genetic risk for MI in individuals with CKD.
-
References
- 1 Best PJ, Lennon R, Ting HH. et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119.
- 2 Mann JF, Gerstein HC, Pogue J. et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
- 3 Coresh J, Byrd-Holt D, Astor BC. et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188.
- 4 Imai E, Horio M, Iseki K. et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156-163.
- 5 Go AS, Chertow GM, Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
- 6 Keith DS, Nichols GA, Gullion CM. et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
- 7 Anavekar NS, McMurray JJ, Velazquez EJ. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
- 8 Yamada Y, Ichihara S, Nishida T. Molecular genetics of myocardial infarction. Genomic Med 2008; 02: 7-22.
- 9 Yamada Y, Matsuo H, Segawa T. et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost 2006; 96: 220-227.
- 10 Imai E, Matsuo S, Makino H. et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 2008; 31: 1101-1107.
- 11 Levey AS, Eckardt KU, Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
- 12 Itoh Y, Mizuki N, Shimada T. et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005; 57: 717-729.
- 13 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approch to multiple testing. J Royal Stat Soc B 1995; 57: 289-300.
- 14 Sjoland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98: 339-345.
- 15 McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens 2004; 13: 591-600.
- 16 Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
- 17 Meade TW, North WR, Chakrabarti R. et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 01: 1050-1054.
- 18 Hahn MW, Rockman MV, Soranzo N. et al. Population genetic and phylogenetic evidence for positive selection on regulatory mutations at the factor VII locus in humans. Genetics 2004; 167: 867-877.
- 19 Iacoviello L, Di Castelnuovo A, De Knijff P. et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
- 20 McCarthy JJ, Parker A, Salem R. et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004; 41: 334-341.
- 21 Nishihama K, Yamada Y, Matsuo H. et al. Association of gene polymorphisms with myocardial infarction in individuals with or without conventional coronary risk factors. Int J Mol Med 2007; 19: 129-141.
- 22 Lane A, Green F, Scarabin PY. et al. Factor VII Arg/ Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-127.
- 23 Doggen CJ, Manger Cats V, Bertina RM. et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-285.
- 24 Ye Z, Liu EH, Higgins JP. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
- 25 Girelli D, Russo C, Ferraresi P. et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-780.
- 26 Gelb BD, Zhang J, Cotter PD. et al. Physical mapping of the human connexin 40 (GJA5), flavin-containing monooxygenase 5, and natriuretic peptide receptor a genes on 1q21. Genomics 1997; 39: 409-411.
- 27 Makino A, Platoshyn O, Suarez J. et al. Downregulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice. Am J Physiol Cell Physiol 2008; 295: C221-230.
- 28 Baier LJ, Sacchettini JC, Knowler WC. et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95: 1281-1287.
- 29 Guettier JM, Georgopoulos A, Tsai MY. et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005; 90: 1705-1711.